click below
click below
Normal Size Small Size show me how
Pharm 5018 ETSU NP
Ch 3 Drug Prescribing
| Question | Answer |
|---|---|
| The Process of Rational Drug Prescribing | Define the patient’s problem/Specify the therapeutic objective/Collaborate with the patient/Choose the treatment/Educate the pt/Monitor effectiveness. |
| Define the Patient’s Problem | Assess patient. Develop working and differential diagnosis. Use diagnostic tests to confirm. |
| Specify the Therapeutic Objective | Goal of treatment: Cure the disease? Relieve symptoms of disease? Replacing deficiencies (e.g., insulin)? Long-term prevention? |
| Collaborate With the Patient | The World Health Organization recommends including patient in developing therapeutic objective of drug therapy. |
| Choose the Treatment | Use evidence-based guidelines/Individualize for each patient/Novice providers use analytic, step-by-step decision making/Experienced providers use exp & pattern recognition/Use more systematic approach with complex patients. |
| The I Can PresCribE A Drug Mnemonic | Indication - Contraindications - Precautions - Cost/Compliance - Efficacy - Adverse effects - Dose/Duration/Direction |
| Start Treatment | Patient usually fills prescription at pharmacy. When writing prescription, discuss whether pt has ability to pay for prescrip Insurance copays/Generics often less expensive $4 retail lists |
| Educate the Patient | Poor adherence contributes to worsening disease, hospital admissions, and death. Pt ed at the 5th or 6th gr level/Include in ed purpose of medication/Instructions for administration Adverse drug reactions (ADRs) |
| Monitor Effectiveness | Passive monitoring: Pt is ed on expected outcome and instructed to contact provider. Active monitoring: f/u lab tests or monitoring to measure therapeutic effectiveness |
| Drug Factors Influencing Drug Selection | Pharmacokinetic factors/Pharmacodynamic factors Therapeutic factors/Safety /Cost (to patient and to society)/Patient factors/Provider factors |
| Pharmacokinetic Factors | Bioavailability /CYP 450 metabolism/Renal /elimination/Dose-concentration curve /Half-life |
| Therapeutic Factors | Evidence for therapeutic impact: Clinical trials/Clinical practice guidelines/Systematic reviews Randomized controlled trials: Extrapolate with caution |
| Safety | Safety profile is taken into consideration/ varies by population: Teratogens/Liver or renal disease/Drug allergy MedWatch report U.S. Food and Drug Administration advisories |
| Cost | Cost to patient: High drug cost outlay by patient may decrease adherence/Ask about prescription drug coverage/Consider $4 retail pharmacy lists. Cost to society: Thoughtful prescribing considers cost to health system. |
| Patient Factors | Previous ADRs/Health beliefs Current drug therapy: Drug interactions/Consult PharmD regarding complex drug regimens. Patient age/Pregnancy |
| Provider Factors | Ease of prescribing or monitoring Formularies: Nurse practitioners need to be familiar with the formulary they are allowed to prescribe. Personal formulary: Each provider develops a small list of drugs they are comfortable prescribing. |
| Influences on Rational Prescribing | Pharmaceutical promotion: May influence prescribing When prescribing recom change: When guidelines change, providers may need to be coached or reeducated regarding appropriate prescribing. |